Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study
Autore:
London, GM; Pannier, B; Guerin, AP; Blacher, J; Marchais, SJ; Darne, B; Metivier, F; Adda, H; Safar, ME;
Indirizzi:
Hop FH Manhes, Serv Hemodialyse, F-91712 Fleury Merogis, France Hop FH Manhes Fleury Merogis France F-91712 91712 Fleury Merogis, France Hop Broussais, Serv Med Interne, F-75674 Paris, France Hop Broussais Paris France F-75674 rv Med Interne, F-75674 Paris, France
Titolo Testata:
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
fascicolo: 12, volume: 12, anno: 2001,
pagine: 2759 - 2767
SICI:
1046-6673(200112)12:12<2759:AOLVHI>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
STAGE RENAL-DISEASE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; DIALYZED UREMIC PATIENTS; DIALYSIS PATIENTS; RISK-FACTORS; PULSE PRESSURE; MASS INDEX; FAILURE; CARDIOMYOPATHY; REGRESSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
45
Recensione:
Indirizzi per estratti:
Indirizzo: London, GM Hop FH Manhes, Serv Hemodialyse, 8 Grande Rue, F-91712 Fleury Merogis, France Hop FH Manhes 8 Grande Rue Fleury Merogis France F-91712 rance
Citazione:
G.M. London et al., "Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study", J AM S NEPH, 12(12), 2001, pp. 2759-2767

Abstract

Left ventricular (LV) hypertrophy (LVH) is a risk factor for mortality in patients with end-stage renal disease (ESRD). Whether the attenuation of LVH has a positive effect on survival of patients with ESRD has not been documented. The aim of this study was to determine the effect of parallel treatment of hypertension and anemia on LV mass (LVM) and to determine the effect of LVM changes on survival. A cohort of 153 patients receiving hemodialysis was studied. The duration of follow-up was 54 +/- 37 mo. All patients had echocardiographic determination of LV dimensions and LVM at baseline and regular intervals until the end of the follow-up period. During the study, BP decreased from (mean +/- SD) 169.4 +/- 29.7/90.2 +/- 15.6 to 146.7 +/- 29/78 +/- 14.1 mmHg (P < 0.001), and hemoglobin increased from 8.65 <plus/minus> 1.65 to 10.5 +/- 1.45 g/dl (P < 0.001). The LV end-diastolic diameter and mean wall thickness decreased from 56.6 <plus/minus> 6.5 to 54.8 +/- 6.5 min (P < 0.001), and from 10.4 <plus/minus> 1.6 to 10.2 +/- 1.6 mm (P < 0.05), respectively. The LVM decreased from 290 <plus/minus> 80 to 264 +/- 86 g (P < 0.01). Fifty-eight deaths occurred, 38 attributed to cardiovascular (CV) disease and 20 attributed to non-CV causes. According to Cox analyses after adjustment for age,,,ender, diabetes, history of CV disease, and all nonspecific CV risk factors, LVM regression positively affected the survival. The hazard risk ratio associated with a 10% LVM decrease was 0.78 (95%confidence interval, 0.63 to 0.92) for all-causes mortality and 0.72 (95% confidence interval, 0.51 to 0.90) for mortality due to CV disease. These results show that a partial LVH regression in patients with ESRD had a favorable and independent effect on patients' all-cause and CV survival.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 15:32:17